BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 11595719)

  • 1. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting by conjugation of DHA to paclitaxel.
    Bradley MO; Swindell CS; Anthony FH; Witman PA; Devanesan P; Webb NL; Baker SD; Wolff AC; Donehower RC
    J Control Release; 2001 Jul; 74(1-3):233-6. PubMed ID: 11489499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
    Wolff AC; Donehower RC; Carducci MK; Carducci MA; Brahmer JR; Zabelina Y; Bradley MO; Anthony FH; Swindell CS; Witman PA; Webb NL; Baker SD
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3589-97. PubMed ID: 14506145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
    Sparreboom A; Wolff AC; Verweij J; Zabelina Y; van Zomeren DM; McIntire GL; Swindell CS; Donehower RC; Baker SD
    Clin Cancer Res; 2003 Jan; 9(1):151-9. PubMed ID: 12538463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
    Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
    Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
    Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
    Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S
    Br J Cancer; 2004 Nov; 91(9):1651-5. PubMed ID: 15494716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
    Guillemard V; Saragovi HU
    Cancer Res; 2001 Jan; 61(2):694-9. PubMed ID: 11212270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice.
    Connolly JM; Gilhooly EM; Rose DP
    Nutr Cancer; 1999; 35(1):44-9. PubMed ID: 10624705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
    Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S; Wientjes MG; Walsh C; Au JL
    Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.